Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
578
Stocks News & Analysis
stocks
Why don’t good returns guarantee a 5-star rating?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,932.40 | 64.90 | -0.72% |
| CAC 40 | 8,216.78 | 135.22 | -1.62% |
| DAX 40 | 26,045.37 | 553.27 | -2.08% |
| Dow JONES (US) | 50,759.42 | 848.75 | -1.64% |
| FTSE 100 | 10,689.87 | 191.68 | -1.76% |
| HKSE | 23,262.69 | 245.48 | -1.04% |
| NASDAQ | 24,328.38 | 181.38 | -0.74% |
| Nikkei 225 | 59,114.56 | 254.13 | 0.43% |
| NZX 50 Index | 14,264.29 | 42.67 | -0.30% |
| S&P 500 | 7,340.53 | 76.06 | -1.03% |
| S&P/ASX 200 | 8,821.80 | 61.40 | -0.69% |
| SSE Composite Index | 3,582.42 | 2.16 | -0.06% |